New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 26, 2013
07:48 EDTAVNRAvanir Pharmaceuticals receives CHMP opinion for approval of Nuedexta in Europe
Avanir Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Nuedexta, recommending Nuedexta be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause. In addition, the CHMP also recommended approval of two dose strengths of Nuedexta; 20/10 mg and 30/10 mg capsules.
News For AVNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
07:11 EDTAVNRAvanir AVP-923 data looks better than expected, says Piper Jaffray
Piper Jaffray says the Phase II data Avanir presented for AVP-923 in Alzheimer's agitation at the American Neurological Association Monday was better than expected and could open the door for a billion dollar opportunity. It reiterates an Overweight rating on the stock with a $21 price target.
October 13, 2014
16:32 EDTAVNRAvanir Phase 2 AVP-923 study shows improvement in agitation on primary endpoint
Subscribe for More Information
07:33 EDTAVNRAmerican Neurological Association to hold annual meeting
ANA 2014: 139th Annual Meeting is being held in Baltimore on October 12-14.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use